Dias da Costa Juvenal Soares, Fuchs Sandra Costa, Olinto Maria Teresa Anselmo, Gigante Denise Petrucci, Menezes Ana Maria Baptista, Macedo Silvia, Gehrke Sabrina
Departamento de Medicina, Faculdade de Medicina, Universidade Federal de Pelotas, Rio Grande do Sul, Brazil.
Sao Paulo Med J. 2002 Jul 4;120(4):100-4. doi: 10.1590/s1516-31802002000400002.
The cost-effectiveness of the treatment of hypertension has scarcely been investigated in population-based studies. Most data come from secondary analysis of clinical trials and administrative sources.
To describe the health care costs for outpatient hypertension treatment in comparison with diabetes mellitus and chronic bronchitis, and to examine the cost-effectiveness of different classes of antihypertensive drugs.
Cross-sectional population-based study.
Urban area of Pelotas, southern Brazil.
Individuals aged 20-69 years, identified through multi-stage probability sampling.
Participants were interviewed at home. Demographic data, education, income, smoking, previous morbidity, use of medicine and other characteristics were assessed via a pre-tested questionnaire, and blood pressure while seated was measured in a standardized way.
Approximately 24% of the participants had high blood pressure or were taking antihypertensive drugs, and among these, 33% had had a physician consultation during the month preceding the interview. The monthly mean costs of care for hypertension (R$ 89.90), diabetes (R$ 80.64) and bronchitis (R$ 92.63) were similar. Treatment of hypertension consumed 22.9% of the per-capita income, corresponding to R$ 392.76 spent per year exclusively on antihypertensive drugs. Most of the direct costs associated with hypertension and diabetes were spent on drugs, while patients with bronchitis had greater expenditure on appointments. The cost-effectiveness relationship was more favorable for diuretics (116.3) and beta blockers (228.5) than for ACE inhibitors (608.5) or calcium channel blockers (762.0).
The costs of hypertension care are mainly dependent on the expenditure on blood pressure-lowering drugs. Treatment of hypertension with diuretics or beta blockers was more cost-effective than treatment with ACE inhibitors and calcium channel blockers.
基于人群的研究中几乎未对高血压治疗的成本效益进行过调查。大多数数据来自临床试验的二次分析和行政来源。
描述门诊高血压治疗与糖尿病和慢性支气管炎相比的医疗保健成本,并研究不同类别降压药物的成本效益。
基于人群的横断面研究。
巴西南部佩洛塔斯的市区。
通过多阶段概率抽样确定的20至69岁个体。
在家中对参与者进行访谈。通过预先测试的问卷评估人口统计学数据、教育程度、收入、吸烟情况、既往发病率、用药情况和其他特征,并以标准化方式测量坐位血压。
约24%的参与者患有高血压或正在服用降压药物,其中33%在访谈前一个月内曾咨询过医生。高血压(89.90雷亚尔)、糖尿病(80.64雷亚尔)和支气管炎(92.63雷亚尔)的月平均护理成本相似。高血压治疗花费了人均收入的22.9%,相当于每年仅用于降压药物的支出为392.76雷亚尔。与高血压和糖尿病相关的大多数直接成本用于药物,而支气管炎患者在预约方面的支出更高。利尿剂(116.3)和β受体阻滞剂(228.5)的成本效益关系比ACE抑制剂(608.5)或钙通道阻滞剂(762.0)更有利。
高血压护理成本主要取决于降压药物的支出。使用利尿剂或β受体阻滞剂治疗高血压比使用ACE抑制剂和钙通道阻滞剂更具成本效益。